Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke [Brief Reports]
Conclusions—
In patients with acute ischemic stroke, alteplase 0.9 mg/kg caused significant disruption of the fibrinolytic system, whereas tenecteplase 0.25 mg/kg did not, consistent with the trend toward lower intracerebral hemorrhage incidence with tenecteplase in the ATTEST study.
Clinical Trial Registration—
URL: http://www.clinicaltrials.gov. Unique identifier: NCT01472926.
Source: Stroke - Category: Neurology Authors: Huang, X., Moreton, F. C., Kalladka, D., Cheripelli, B. K., MacIsaac, R., Tait, R. C., Muir, K. W. Tags: Treatment, Ischemic Stroke, Thrombosis Brief Reports Source Type: research
More News: Activase | Clinical Trials | Hemorrhagic Stroke | Hypofibrinogenemia | Ischemic Stroke | Neurology | Stroke | Study | Thrombosis